As innovations in cancer care transform the disease into a chronic illness, the survivorship population encompasses more than early stage patients but survivors of long term metastatic disease as well, explains Crystal S. Denlinger, MD, Fox Chase Cancer Center in Philadelphia.
As innovations in cancer care transform the disease into a chronic illness, Crystal S. Denlinger, MD, Fox Chase Cancer Center in Philadelphia, says that the survivorship population encompasses more than early stage patients but survivors of long term metastatic disease as well.
Many of the challenges that Dr Denlinger says comes along with cancer survivorship is helping the patient come to terms with the new lifestyle changes that treatment and therapy causes. She adds that patients in different stages of survivorship require different care methods.
“Survivorship care has to be broad enough and as providers, we have to be willing to provide care across those three components of care but with different focuses depending on what stage of disease or what component of survivorship an individual person is living in,”Dr Denlinger says.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More